PREFER is a five-year project funded by the European Commission's Innovative Medicines Initiative (IMI) 2 programme to evaluate different ways of assessing clinical patient preferences. The project will establish recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to include patient perspectives on benefits and risks of medicinal products.
The research project will run from October 2016 to September 2021.
- PREFER Objectives
Over the next five years, patient preference studies will be performed in both academic and industry settings. The gained experience will provide a better understanding of what will be a recommended best-practice approach to patient-preference studies. The project will also show how patient preference studies can give valuable information to support decision making for regulators and HTA bodies.
PREFER is divided into four 'work packages'. The methodology work package looks at the concerns stakeholders have around the use of patient-preference studies. Based on what they find, they will make recommendations about what methodologies to use in case studies that the case study work package will design and carry out. After evaluating the case studies, Finally, the recommendations work package will take over and draft recommendations based on the work. The management work package will make sure this work is done on time.
- ECPC's Role
The European Cancer Patient Coalition is one of the four patient organisations in the Patient Advisory Group of the project. The role of ECPC is to lead the Patient Advisory Group and to ensure that the methodologies identified are consistent with the specific views, experiences and preferences of patients. ECPC will also contribute to the final recommendations and to the successful dissemination of the project's deliverables.
- Public Private Partnership
Uppsala University and Novartis lead a new public-private research project "Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER)" under the Innovative Medicines Initiative 2 Joint Undertaking (Grant Agreement N° 115966). IMI is a partnership between the European Union’s Horizon 2020 programme and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
- Contact Points
Patient Advocacy Group: Isabelle Manneh-Vangramberen, European Cancer Patient Coalition's Projects Coordinator
Project Coordinator: Mats G. Hansson, Professor of Biomedical Ethics, Centre for Research Ethics & Bioethics (CRB), Uppsala University
Project Leader: Conny Berlin, Global Head Quantitative Safety & Epidemiology Novartis
PREFER is funded by the Innovative Medicines Intiative (IMI): a part of the EU Horizon 2020 Programmme.
- Project Website